V1RI3 Inhibitors
V1RI3 inhibitors are a class of chemical compounds designed to specifically interact with and inhibit the function of the V1RI3 protein. The V1RI3 protein is a biological molecule that plays a role in various cellular processes. Inhibitors targeting this protein are structurally diverse, reflecting the complex nature of the protein's active site and the interactions required for effective inhibition. The design of these inhibitors often involves meticulous structural analysis of the V1RI3 protein, including its three-dimensional conformation and the dynamic changes it may undergo during biological processes. The chemical structures of V1RI3 inhibitors typically incorporate functional groups capable of forming strong and selective interactions with amino acid residues within the target protein's active site. Such interactions are crucial for the inhibition process as they disrupt the protein's natural function.
The development of V1RI3 inhibitors is a sophisticated undertaking that requires an in-depth understanding of medicinal chemistry and protein biochemistry. Scientists utilize various techniques such as X-ray crystallography, computational modeling, and structure-activity relationship (SAR) studies to refine the efficacy and selectivity of these inhibitors. These studies help identify key molecular fragments that are critical for binding and inhibiting the V1RI3 protein, thereby guiding the synthesis of more potent and selective compounds. The inhibitors may act through different mechanisms, such as competitive inhibition, where the inhibitor molecule competes with natural substrates or ligands for binding to the active site, or non-competitive inhibition, where the inhibitor binds to a different part of the protein, causing a conformational change that reduces its activity. The precise mechanism of action can be influenced by the inhibitor's structure and the unique characteristics of the V1RI3 protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3Ks, wortmannin can disrupt the PI3K/AKT signaling pathway, which is critical for many cellular processes including survival, proliferation, and metabolism. Inhibition of this pathway can indirectly lead to reduced activity of V1RI3 if V1RI3 activity is dependent on signals downstream of PI3K activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar in function to Wortmannin, that specifically blocks the ATP binding site of PI3K. By halting PI3K activity, LY294002 diminishes AKT phosphorylation and activation, potentially leading to a decrease in V1RI3 activity if V1RI3 is regulated by AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that impedes the mTORC1 complex, which can regulate protein synthesis and cell growth. The inhibition of mTORC1 might negatively impact V1RI3 activity if V1RI3 is linked to growth factor signaling that converges on the mTOR pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor that can affect a wide range of kinases. If V1RI3 function is contingent on phosphorylation by specific kinases, staurosporine may reduce V1RI3 activity by preventing such phosphorylation events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. Inhibition of MEK leads to decreased activation of ERK, which may downregulate V1RI3 activity if V1RI3 is modulated by ERK-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress- and cytokine-induced signal transduction pathways. By inhibiting JNK, SP600125 could decrease V1RI3 activity if V1RI3 is regulated through pathways that involve JNK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in inflammatory responses and stress signaling. If V1RI3 is modulated by signaling pathways that include p38 MAPK, the inhibition by SB203580 could result in decreased V1RI3 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, preventing the activation of the downstream kinase ERK. If the activity of V1RI3 is influenced by ERK signaling, U0126-mediated MEK inhibition could lead to reduced V1RI3 function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. Src kinases can influence various signaling pathways, including those related to cell proliferation and survival. If V1RI3 is activated by Src kinase signaling, inhibition by PP2 could decrease V1RI3 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt the degradation of proteins involved in cell cycle regulation and survival. If V1RI3 stability or activity is controlled by proteasome-mediated degradation, bortezomib may indirectly decrease V1RI3 activity by altering protein turnover. | ||||||